Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award: Doctoral Foreign Study Award (DFSA)

Direct Payment

$105,000.00

Next-generation precision genome engineering of primary cells with cell-penetrating complexes

FY 2023-24

Summary
With more than 3000 genes in the human genome linked to pathogenesis, genome engineering has gained momentum as a targeted approach to examine or treat disease. While CRISPR-Cas nucleases have been at the forefront of such efforts due to their ability to efficiently knock out genes, they come with undesired by-products and are highly inefficient for gene replacement applications. Novel biotechnological tools, such as Base Editors (BEs) and Prime Editors (PEs), have been developed to overcome CRISPR-Cas limitations. These tools comprise of catalytically impaired Cas proteins and DNA-modifying enzymes or reverse transcriptases that permit the introduction of precise gene mutations. For these tools to provide utility in understanding disease mechanisms or serve as therapeutics, they need to be delivered into primary cells - cells directly obtained from animal or human tissues. Yet, delivering gene editing machinery in primary cells remains a major challenge. Current delivery approaches include electroporation, lipid nanoparticles or viral vectors, which are limited by their toxicity, immunogenicity, and potential viral integration, respectively. Recently, in collaboration with the lab of Junwei Shi, our group engineered Cas proteins with cell-penetrating peptides to knock out genes in primary cells. However, given that CRISPR-Cas nucleases are limited to gene inactivation, it is imperative to devise a non-toxic delivery platform for novel gene editing machinery that can rewrite genes. Towards that goal, in this proposal, we will develop a direct, cell-penetrating, modular approach to facilitate the delivery of next-generation genome engineering tools capable of introducing any precise edit into primary cells. We will deliver tunable PEs and BEs in model primary cells, such as primary hematopoietic stem cells. We will use these tools to newly model mutations in the epigenetic regulator TET2 that have been linked to skewed differentiation and hematopoietic neoplasms.
Program
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Location
Pennsylvania, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
495448
Name
Barka Aleksia
Region
Pennsylvania
Country
United States of America
Orgtype
Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Next-generation precision genome engineering of primary cells with cell-penetrating complexes
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Keyworddelim
Delivering Gene Editing Tools In Primary Cells; Dna-Modifying Enzymes; Gene Editing; Protein Engineering; Protein-Fusion Technologies
Abstract
With more than 3000 genes in the human genome linked to pathogenesis, genome engineering has gained momentum as a targeted approach to examine or treat disease. While CRISPR-Cas nucleases have been at the forefront of such efforts due to their ability to efficiently knock out genes, they come with undesired by-products and are highly inefficient for gene replacement applications. Novel biotechnological tools, such as Base Editors (BEs) and Prime Editors (PEs), have been developed to overcome CRISPR-Cas limitations. These tools comprise of catalytically impaired Cas proteins and DNA-modifying enzymes or reverse transcriptases that permit the introduction of precise gene mutations. For these tools to provide utility in understanding disease mechanisms or serve as therapeutics, they need to be delivered into primary cells - cells directly obtained from animal or human tissues. Yet, delivering gene editing machinery in primary cells remains a major challenge. Current delivery approaches include electroporation, lipid nanoparticles or viral vectors, which are limited by their toxicity, immunogenicity, and potential viral integration, respectively. Recently, in collaboration with the lab of Junwei Shi, our group engineered Cas proteins with cell-penetrating peptides to knock out genes in primary cells. However, given that CRISPR-Cas nucleases are limited to gene inactivation, it is imperative to devise a non-toxic delivery platform for novel gene editing machinery that can rewrite genes. Towards that goal, in this proposal, we will develop a direct, cell-penetrating, modular approach to facilitate the delivery of next-generation genome engineering tools capable of introducing any precise edit into primary cells. We will deliver tunable PEs and BEs in model primary cells, such as primary hematopoietic stem cells. We will use these tools to newly model mutations in the epigenetic regulator TET2 that have been linked to skewed differentiation and hematopoietic neoplasms.
Competitiondate
202310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Barka, Aleksia
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
Direct Payment - $105,000 Grant (2023-24) | Canada Spends